Research Topics
| A NarayanaSummaryAffiliation: New York University School of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Involved field radiation therapy after surgical resection of solitary brain metastases--mature resultsEileen P Connolly
Corresponding Author Ashwatha Narayana, MD, Professor, Department of Radiation Oncology, New York University Langone Medical Center, 550 1st Avenue, New York, NY 11016
Neuro Oncol 15:589-94. 2013..Conclusion For patients with newly diagnosed single brain metastases treated with surgical resection, postoperative IFRT to the resection cavity achieves reasonable rates of local control and is an excellent alternative to WBRT...- Antiangiogenic therapy in the management of brain tumors: a clinical overviewSaroj Kunnakkat
Department of Radiation Oncology, New York University Langone Medical Center, NY 10016, USA
Cancer Chemother Pharmacol 70:353-63. 2012..While many have been shown to be effective with limited toxicity, some tumors are able to adopt escape mechanisms. Further research is needed in the development of effective multi-targeted agents to reduce these effects... - A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastomaAshwatha Narayana
Departments of Radiation Oncology, New York University Langone Medical Center, New York, New York 10016, USA
J Neurosurg 116:341-5. 2012..The authors conducted a prospective clinical trial to test the effectiveness of bevacizumab, an inhibitor of VEGF, in newly diagnosed GBM... 
High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary resultsAshwatha Narayana
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Brachytherapy 6:157-63. 2007..We report our preliminary results in patients with recurrent H&N cancers treated with interstitial HDRBT...- Hypofractionated stereotactic radiotherapy using intensity-modulated radiotherapy in patients with one or two brain metastasesAshwatha Narayana
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
Stereotact Funct Neurosurg 85:82-7. 2007.... - Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade gliomaAshwatha Narayana
Department of Radiation Oncology, New York University Medical Center, New York, NY 11016, USA
Int J Radiat Oncol Biol Phys 72:383-9. 2008..The purpose of this study is to test the feasibility of using bevacizumab with chemoradiation in the primary management of high-grade glioma... - Use of MR spectroscopy and functional imaging in the treatment planning of gliomasA Narayana
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
Br J Radiol 80:347-54. 2007..A Phase I IMRT dose intensification trial in gliomas using this information is planned... - Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survivalAshwatha Narayana
Department of Radiation Oncology, New York University Medical Center, New York, New York, USA
J Neurosurg 110:173-80. 2009..However, it is not clear if the responses are related to vascular changes or due to antitumoral effects. The authors report the mature results of a clinical study of bevacizumab-based treatment of recurrent high-grade gliomas... 
Bevacizumab in recurrent high-grade pediatric gliomasAshwatha Narayana
Department of Radiation Oncology, New York University Langone Medical Center, New York, New York 10016, USA
Neuro Oncol 12:985-90. 2010..However, the radiological response rate, response duration, and survival appeared inferior in pediatric patients. Genetic differences in pediatric gliomas might account for this difference...- Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric resultsAshwatha Narayana
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 64:892-7. 2006..To report preliminary clinical and dosimetric data from intensity-modulated radiotherapy (IMRT) for malignant gliomas... - High-grade glioma before and after treatment with radiation and Avastin: initial observationsIngeborg Fischer
Department of Pathology, New York University Medical Center, New York, NY, USA
Neuro Oncol 10:700-8. 2008..While the phenomena we describe may not be specific to Avastin, they demonstrate the potential of tissue-based analysis for the discovery of clinically relevant treatment response biomarkers... - Therapeutic targets in malignant glioblastoma microenvironmentMary Helen Barcellos-Hoff
Department of Radiation Oncology, New York University, Langone School of Medicine, New York, NY 10016, USA
Semin Radiat Oncol 19:163-70. 2009.... - Salvage re-irradiation for recurrent head and neck cancerNancy Lee
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 68:731-40. 2007..To present a retrospective review of treatment outcomes for recurrent head and neck (HN) cancer patients treated with re-irradiation (re-RT) at a single medical center... - Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine gliomaRajni Sethi
Department of Radiation Oncology, New York University Langone Medical Center, 566 First Avenue, New York, NY 10014, USA
J Neurooncol 102:121-7. 2011..All patients should undergo routine craniospinal imaging at diagnosis and follow-up. Central nervous system prophylaxis should be considered in future clinical trials... - Magnetic resonance spectroscopy imaging (MRSI) and brain functional magnetic resonance imaging (fMRI) for radiotherapy treatment planning of gliomaJenghwa Chang
Radiation Oncology Department, New York University Langone Medical Center, 556 First Avenue, New York, NY 10016, USA
Technol Cancer Res Treat 7:349-62. 2008..An IMRT (intensity-modulated radiotherapy) dose painting plan for this case is also presented using the fused MRSI and fMRI to delineate the clinical target volumes and Broca's area... - Feasibility study of intensity-modulated radiotherapy (IMRT) treatment planning using brain functional MRIJenghwa Chang
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Med Dosim 33:42-7. 2008..In conclusion, it is feasible to incorporate the fMRI information into the RT treatment planning. IMRT planning allows a significant reduction in RT dose to the PMC regions, especially if the region does not lie within the PTV... - Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancersNancy Y Lee
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 69:459-68. 2007..To perform a retrospective review of laryngeal/hypopharyngeal carcinomas treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT)... - (32)P radioisotope therapy for recurrent pilocytic astrocytomaAshwatha Narayana
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Brachytherapy 4:171-3. 2005..32)P is a pure beta-emitter that has a depth of penetration of 2-3 mm and can be useful in the treatment of cystic lesions. Its effectiveness in the treatment of a selected brain tumor is illustrated here... - Geometric factors influencing dosimetric sparing of the parotid glands using IMRTMargie A Hunt
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 66:296-304. 2006..To determine the relationship between the parotid volume, parotid-planning target volume (PTV) overlap, and dosimetric sparing of the parotid with intensity-modulated radiation therapy (IMRT)... - Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experienceFernando F de Arruda
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10022, USA
Int J Radiat Oncol Biol Phys 64:363-73. 2006..Treatment toxicity was acceptable even in the setting of concurrent chemotherapy. Long-term follow-up is needed to confirm these preliminary findings... - Image-fusion of MR spectroscopic images for treatment planning of gliomasJenghwa Chang
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
Med Phys 33:32-40. 2006..In conclusion, an image-fusion protocol was developed that successfully incorporates MRSI information into the IMRT treatment plan for glioma... - Accuracy and feasibility of cone-beam computed tomography for stereotactic radiosurgery setupJenghwa Chang
Medical Physics Department, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
Med Phys 34:2077-84. 2007..34 mm, SD = 0.33 mm). In conclusion, CBCT can be used to guide SRS treatment setup with accuracy comparable to the currently used frame-based stereotactic radiosurgery systems provided that intra-treatment patient motion is prevented... - Decreasing temporal lobe dose with five-field intensity-modulated radiotherapy for treatment of pituitary macroadenomasPreeti K Parhar
Department of Radiation Oncology, New York University School of Medicine, New York, USA
Int J Radiat Oncol Biol Phys 78:379-84. 2010.... - A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinomaNancy Y Lee
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 66:966-74. 2006..intensity-modulated radiotherapy (IMRT) in the setting of concurrent chemotherapy (CT) for locally advanced oropharyngeal carcinoma... - Effect of MLC leaf width and PTV margin on the treatment planning of intensity-modulated stereotactic radiosurgery (IMSRS) or radiotherapy (IMSRT)Jenghwa Chang
Medical Physics Department, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Med Dosim 34:110-6. 2009..For IMSRS, where highly accurate setup and small PTV margins are routinely employed, the use of 5-mm MLC is therefore less desirable... - Functional MRI for radiotherapy of gliomasJenghwa Chang
Department of Radiation Oncology, New York Presbyterian Hospital Weill Cornell Medical College, 525 E 68th St, Box 25, New York, NY 10065, USA
Technol Cancer Res Treat 9:347-58. 2010.... - Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancerBenjamin D Rosenbluth
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 63:1419-26. 2005..Ideal planning target volume doses have yet to be determined. Additional patients and long-term follow-up are needed to confirm these preliminary findings and to clarify late toxicities... - Central nervous system cancers: Clinical Practice Guidelines in OncologySteven S Brem
J Natl Compr Canc Netw 3:644-90. 2005 - Small vestibular schwannomas with no hearing: comparison of functional outcomes in stereotactic radiosurgery and microsurgeryDaniel H Coelho
Department of Otolaryngology Head and Neck Surgery, Virginia Commonwealth University, Richmond, Virginia, USA
Laryngoscope 118:1909-16. 2008..Few have systematically compared issues of dysequilibrium. By studying only patients with small tumors and no hearing, we sought to minimize confounding variables... - Plaque radiotherapy for choroidal and ciliochoroidal melanomas with limited nodular extrascleral extensionJames J Augsburger
Ocular Oncology Service, Department of Ophthalmology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0527, USA
Can J Ophthalmol 39:380-7. 2004..Currently available clinical information regarding management of posterior uveal melanomas complicated by nodular extrascleral extension is inadequate to determine the role, if any, for plaque radiotherapy in such patients...